MREO — Mereo BioPharma Balance Sheet
0.000.00%
Last trade - 00:00- $438.84m
- $376.36m
Annual balance sheet for Mereo BioPharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | 20-F | 10-K | 10-K |
| Standards: | IFRS | IFRS | IFRS | USG | USG |
| Status: | fx Final | fx Final | fx Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 32.1 | 128 | 68.1 | 57.4 | 69.8 |
| Net Total Receivables | 6.34 | 3.01 | 3.23 | 2.55 | 1.47 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 40.6 | 134 | 75.2 | 63.8 | 74.8 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.15 | 3.42 | 2.21 | 1.65 | 0.984 |
| Net Intangible Assets | |||||
| Total Assets | 86.1 | 165 | 107 | 66.5 | 76.4 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11.7 | 13.2 | 29.9 | 9.49 | 13.8 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 107 | 46.4 | 31.7 | 16 | 15.4 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | -20.5 | 119 | 74.8 | 50.5 | 61 |
| Total Liabilities & Shareholders' Equity | 86.1 | 165 | 107 | 66.5 | 76.4 |
| Total Common Shares Outstanding |